61 related articles for article (PubMed ID: 35223529)
41. RET Inhibitors in Non-Small-Cell Lung Cancer.
Cascetta P; Sforza V; Manzo A; Carillio G; Palumbo G; Esposito G; Montanino A; Costanzo R; Sandomenico C; De Cecio R; Piccirillo MC; La Manna C; Totaro G; Muto P; Picone C; Bianco R; Normanno N; Morabito A
Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503226
[TBL] [Abstract][Full Text] [Related]
42. Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
Sun F; McCoach CE
Curr Treat Options Oncol; 2021 Jun; 22(8):72. PubMed ID: 34165651
[TBL] [Abstract][Full Text] [Related]
43. Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer.
Ferrara R; Auger N; Auclin E; Besse B
J Thorac Oncol; 2018 Jan; 13(1):27-45. PubMed ID: 29128428
[TBL] [Abstract][Full Text] [Related]
44. Cabozantinib for the treatment of non-small cell lung cancer with KIF5B-RET fusion. An example of swift repositioning.
Song M; Kim SH; Yoon SK
Arch Pharm Res; 2015 Dec; 38(12):2120-3. PubMed ID: 26377589
[TBL] [Abstract][Full Text] [Related]
45. Pralsetinib: First Approval.
Markham A
Drugs; 2020 Nov; 80(17):1865-1870. PubMed ID: 33136236
[TBL] [Abstract][Full Text] [Related]
46. Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?
Ou SH; Soo RA; Kubo A; Kawaguchi T; Ahn MJ
Front Oncol; 2014; 4():58. PubMed ID: 24744988
[TBL] [Abstract][Full Text] [Related]
47.
Osta BE; Ramalingam SS
JTO Clin Res Rep; 2020 Sep; 1(3):100050. PubMed ID: 34589946
[TBL] [Abstract][Full Text] [Related]
48. Research Progress on RET Fusion in Non-Small-Cell Lung Cancer.
Zhao L; Mei Q; Yu Y; Wang N; Zhang D; Liao D; Zuo J; Xie H; Jia Y; Kong F
Front Oncol; 2022; 12():894214. PubMed ID: 35707347
[TBL] [Abstract][Full Text] [Related]
49. Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis.
Xu YP; Li B; Xu XL; Mao WM
Medicine (Baltimore); 2015 Jun; 94(23):e879. PubMed ID: 26061306
[TBL] [Abstract][Full Text] [Related]
50. Therapeutic strategies in RET gene rearranged non-small cell lung cancer.
Drusbosky LM; Rodriguez E; Dawar R; Ikpeazu CV
J Hematol Oncol; 2021 Mar; 14(1):50. PubMed ID: 33771190
[TBL] [Abstract][Full Text] [Related]
51. Neoadjuvant therapy for resectable non-small cell lung cancer with mediastinal lymph node involvement.
Tieu BH; Sanborn RE; Thomas CR
Thorac Surg Clin; 2008 Nov; 18(4):403-15. PubMed ID: 19086609
[TBL] [Abstract][Full Text] [Related]
52. Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives.
Fancelli S; Caliman E; Mazzoni F; Brugia M; Castiglione F; Voltolini L; Pillozzi S; Antonuzzo L
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33806299
[TBL] [Abstract][Full Text] [Related]
53. Targeting RET-rearranged non-small-cell lung cancer: future prospects.
Bronte G; Ulivi P; Verlicchi A; Cravero P; Delmonte A; Crinò L
Lung Cancer (Auckl); 2019; 10():27-36. PubMed ID: 30962732
[TBL] [Abstract][Full Text] [Related]
54. Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue.
Takamori S; Matsubara T; Haratake N; Toyokawa G; Fujishita T; Toyozawa R; Ito K; Yamaguchi M; Taguchi K; Okamoto T; Seto T
Front Oncol; 2021; 11():704084. PubMed ID: 34497761
[TBL] [Abstract][Full Text] [Related]
55. Surgical resection of advanced non-small cell lung cancer after a response to EGFR-TKI: presentation of two cases and a literature review.
Yamamoto Y; Kodama K; Maniwa T; Takeda M
J Cardiothorac Surg; 2017 Nov; 12(1):98. PubMed ID: 29169381
[TBL] [Abstract][Full Text] [Related]
56. Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA-IIIB) non-small-cell lung cancer: long-term results according to downstaging.
Trodella L; Granone P; Valente S; Margaritora S; Macis G; Cesario A; D'Angelillo RM; Valentini V; Corbo GM; Porziella V; Ramella S; Tonini G; Galetta D; Ciresa M; Vincenzi B; Cellini N
Ann Oncol; 2004 Mar; 15(3):389-98. PubMed ID: 14998840
[TBL] [Abstract][Full Text] [Related]
57. Use of Pralsetinib as Neoadjuvant Therapy for Non-Small Cell Lung Cancer Patient With RET Rearrangement.
Zhou N; Li T; Liang M; Ren F; Ni H; Liu W; Shi T; Xu D; Chen Q; Yu H; Song Z; Zu L; Li S; Xu S
Front Oncol; 2022; 12():848779. PubMed ID: 35223529
[TBL] [Abstract][Full Text] [Related]
58. Current management of
Stinchcombe TE
Ther Adv Med Oncol; 2020; 12():1758835920928634. PubMed ID: 32782485
[TBL] [Abstract][Full Text] [Related]
59. Pralsetinib for the treatment of non-small cell lung cancer.
Fu XY; Dong XD; Zeng L; Ashby CR; Chen ZS; Cheng C
Drugs Today (Barc); 2021 Sep; 57(9):559-569. PubMed ID: 34586104
[TBL] [Abstract][Full Text] [Related]
60. RET fusions in solid tumors.
Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]